Momelotinib therapy for myelofibrosis: a 7-year follow-up

MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis

(2018) Paola Guglielmelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis

(2017) A Pardanani et al.   LEUKEMIA

Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management

(2016) Ayalew Tefferi   AMERICAN JOURNAL OF HEMATOLOGY

Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes

(2016) Eline M.P. Cremers et al.   HAEMATOLOGICA

Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes

(2016) Eline M.P. Cremers et al.   HAEMATOLOGICA

Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia

(2014) Lisa Pieri et al.   AMERICAN JOURNAL OF HEMATOLOGY

Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis

(2014) Ramy A. Abdelrahman et al.   BRITISH JOURNAL OF HAEMATOLOGY

Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis

(2014) A Pardanani et al.   LEUKEMIA

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

(2013) A. Tefferi et al.   BLOOD

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis

(2013) A Pardanani et al.   LEUKEMIA

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

(2010) J. W. Tyner et al.   BLOOD

DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

(2010) Naseema Gangat et al.   JOURNAL OF CLINICAL ONCOLOGY

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients

(2010) D Caramazza et al.   LEUKEMIA

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

(2009) A Pardanani et al.   LEUKEMIA